MCID: HPT070
MIFTS: 39

Hepatosplenic T-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatosplenic T-Cell Lymphoma

MalaCards integrated aliases for Hepatosplenic T-Cell Lymphoma:

Name: Hepatosplenic T-Cell Lymphoma 59 72 33

Characteristics:

Orphanet epidemiological data:

59
hepatosplenic t-cell lymphoma
Age of onset: Adolescent,Adult;

Classifications:



External Ids:

ICD10 33 C86.1
ICD10 via Orphanet 34 C86.1
UMLS via Orphanet 73 C1333984
Orphanet 59 ORPHA86882
UMLS 72 C1333984

Summaries for Hepatosplenic T-Cell Lymphoma

MalaCards based summary : Hepatosplenic T-Cell Lymphoma is related to lymphoma, non-hodgkin, familial and peripheral t-cell lymphoma. An important gene associated with Hepatosplenic T-Cell Lymphoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1). The drugs Infliximab and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include spleen, t cells and bone.

Wikipedia : 75 Hepatosplenic T-cell lymphoma is a rare and generally incurable form of lymphoma, except in the case of... more...

Related Diseases for Hepatosplenic T-Cell Lymphoma

Diseases related to Hepatosplenic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 90, show less)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 30.5 GZMB CD7 ABCB1
2 peripheral t-cell lymphoma 30.2 TIA1 GZMB
3 natural killer cell leukemia 30.2 TIA1 GZMB
4 composite lymphoma 30.0 TIA1 GZMB
5 angioimmunoblastic t-cell lymphoma 29.7 TIA1 GZMB
6 t-cell adult acute lymphocytic leukemia 29.7 TIA1 CD7
7 lymphoma 11.0
8 crohn's disease 10.7
9 splenomegaly 10.6
10 inflammatory bowel disease 10.6
11 lymphoma, hodgkin, classic 10.5
12 pancytopenia 10.5
13 lymphocytic leukemia 10.4
14 acute leukemia 10.4
15 thrombocytopenia 10.4
16 crohn's colitis 10.4
17 chromosomal triplication 10.4
18 lymphoproliferative syndrome 10.3
19 leukemia 10.3
20 t-cell leukemia 10.3
21 leukemia, t-cell, chronic 10.3
22 inflammatory bowel disease 6 10.2
23 myelodysplastic syndrome 10.2
24 exanthem 10.2
25 glomerulonephritis 10.2
26 pustulosis of palm and sole 10.2
27 hemolytic anemia 10.2
28 psoriasis 10.2
29 47,xyy 10.2
30 enteropathy-associated t-cell lymphoma 10.2
31 ring chromosome 7 10.2
32 ring chromosome 10.2
33 hematopoietic stem cell transplantation 10.2
34 helsmoortel-van der aa syndrome 10.2 CD7 ABCB1
35 pfeiffer syndrome 10.1
36 spondyloarthropathy 1 10.1
37 systemic lupus erythematosus 10.1
38 schistosoma mansoni infection, susceptibility/ 10.1
39 anemia, autoimmune hemolytic 10.1
40 immune deficiency disease 10.1
41 myelofibrosis 10.1
42 leukemia, acute myeloid 10.1
43 neuropathy, congenital hypomyelinating, 2 10.1
44 t-cell lymphoma, subcutaneous panniculitis-like 10.1
45 hemophagocytic lymphohistiocytosis 10.1
46 adult t-cell leukemia 10.1
47 anaplastic large cell lymphoma 10.1
48 t-cell large granular lymphocyte leukemia 10.1
49 disseminated intravascular coagulation 10.1
50 inflammatory spondylopathy 10.1
51 common variable immunodeficiency 10.1
52 neutropenia 10.1
53 schistosomiasis 10.1
54 toxic shock syndrome 10.1
55 hepatitis b 10.1
56 autoimmune hepatitis 10.1
57 agammaglobulinemia 10.1
58 membranoproliferative glomerulonephritis 10.1
59 purpura 10.1
60 pneumonia 10.1
61 adult lymphoma 10.1
62 acquired immunodeficiency syndrome 10.1
63 progressive multifocal leukoencephalopathy 10.1
64 spondylitis 10.1
65 ulcerative colitis 10.1
66 myeloid leukemia 10.1
67 lupus erythematosus 10.1
68 48,xyyy 10.1
69 human t-cell leukemia virus type 1 10.1
70 mallory-weiss syndrome 10.1
71 posttransplant acute limbic encephalitis 10.1
72 rare tumor 10.1
73 orbit lymphoma 10.0 TIA1 GZMB
74 lymphomatoid granulomatosis 9.9 TIA1 GZMB
75 lichen sclerosus et atrophicus 9.9 TIA1 GZMB
76 viral esophagitis 9.9 TIA1 GZMB
77 lymphocytic gastritis 9.9 TIA1 GZMB
78 primary cutaneous anaplastic large cell lymphoma 9.9 TIA1 GZMB
79 sezary's disease 9.9 DPP4 CD7
80 panniculitis 9.9 TIA1 GZMB
81 lymphomatoid papulosis 9.9 TIA1 GZMB
82 choriocarcinoma of the testis 9.9 TIA1 GZMB
83 giardiasis 9.9 TIA1 GZMB
84 infiltrating lipoma 9.8 TIA1 GZMB
85 necrotizing sialometaplasia 9.8 TIA1 GZMB
86 ileum cancer 9.8 TIA1 GZMB
87 reticulosarcoma 9.7 TIA1 GZMB
88 b-cell expansion with nfkb and t-cell anergy 9.7 TIA1 GZMB
89 cutaneous t cell lymphoma 9.3 TIA1 GZMB
90 mycosis fungoides 9.1 TIA1 GZMB DPP4 CD7

Graphical network of the top 20 diseases related to Hepatosplenic T-Cell Lymphoma:



Diseases related to Hepatosplenic T-Cell Lymphoma

Symptoms & Phenotypes for Hepatosplenic T-Cell Lymphoma

Drugs & Therapeutics for Hepatosplenic T-Cell Lymphoma

Drugs for Hepatosplenic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 55, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4 170277-31-3
2 Antirheumatic Agents Phase 4
3 Gastrointestinal Agents Phase 4
4 Dermatologic Agents Phase 4
5
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
6
Methylcobalamin Approved, Experimental, Investigational Phase 1, Phase 2 13422-55-4
7
leucovorin Approved Phase 1, Phase 2 58-05-9 143 6006
8
Hydroxocobalamin Approved Phase 1, Phase 2 13422-51-0 11953898 15589840
9
Lenalidomide Approved Phase 2 191732-72-6 216326
10
Denosumab Approved Phase 1, Phase 2 615258-40-7
11
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
13
Cyanocobalamin Approved, Nutraceutical Phase 1, Phase 2 68-19-9 44176380
14
Cobalamin Experimental Phase 1, Phase 2 13408-78-1 6857388
15
tipifarnib Investigational Phase 2 192185-72-1 159324
16 Trace Elements Phase 1, Phase 2
17 Micronutrients Phase 1, Phase 2
18 10-deazaaminopterin Phase 1, Phase 2
19 Folic Acid Antagonists Phase 1, Phase 2
20 Vitamins Phase 1, Phase 2
21 Vitamin B Complex Phase 1, Phase 2
22 Vitamin B9 Phase 1, Phase 2
23 Vitamin B 12 Phase 1, Phase 2
24 Immunologic Factors Phase 1, Phase 2
25 Hematinics Phase 1, Phase 2
26 Folate Phase 1, Phase 2
27 Nutrients Phase 1, Phase 2
28 Anti-Infective Agents Phase 1, Phase 2
29 Immunosuppressive Agents Phase 1, Phase 2
30 Vitamin B12 Phase 1, Phase 2
31 Antiviral Agents Phase 1, Phase 2
32 Antimetabolites Phase 1, Phase 2
33 Antimetabolites, Antineoplastic Phase 1, Phase 2
34 Angiogenesis Inhibitors Phase 2
35 Angiogenesis Modulating Agents Phase 2
36 Antibodies Phase 1, Phase 2
37 Antibodies, Monoclonal Phase 1, Phase 2
38 Immunoglobulins Phase 1, Phase 2
39 Bone Density Conservation Agents Phase 1, Phase 2
40 Protein Kinase Inhibitors Phase 1, Phase 2
41
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
42
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
43
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
44
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
45
Imetelstat Investigational Phase 1 868169-64-6
46 Anti-Bacterial Agents Phase 1
47 Antibiotics, Antitubercular Phase 1
48
Motesanib diphosphate Phase 1 850649-62-6 11450633
49 Nicotinic Acids Phase 1
50 Vitamin B3 Phase 1
51
Methotrexate Approved 1959-05-2, 59-05-2 126941
52
Adalimumab Approved 331731-18-1 16219006
53
Etanercept Approved, Investigational 185243-69-0
54 Liver Extracts
55 Anti-Inflammatory Agents

Interventional clinical trials:

(showing 16, show less)
# Name Status NCT ID Phase Drugs
1 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4 Infliximab;Golimumab
2 A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
3 A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma Completed NCT00322985 Phase 2 Lenalidomide
4 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
5 An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Recruiting NCT02464228 Phase 2 Tipifarnib
6 Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies. Active, not recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
7 Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies. Active, not recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
8 The Safety and Tolerability of Intravitreal Infliximab (Remicade) in Patients With Refractory Diabetic Macular Edema or Choroidal Neovascularization Secondary to Age Related Macular Degeneration- A Pilot Study Unknown status NCT00695682 Phase 1 intravitreal injection of infliximab
9 Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma Completed NCT00963274 Phase 1 Bortezomib;Romidepsin
10 A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas Completed NCT01273090 Phase 1 imetelstat sodium
11 Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation Terminated NCT00996359 Phase 1
12 A Retrospective Review of Reports of Hepatosplenic T-cell Lymphoma in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief [PALGA]), a Database of Pathology Results for The Netherlands Completed NCT00731536
13 Dose Effect Relationship of Methotrexate and Hepatic Fibrosis in Patients With Inflammatory Bowel Disease Completed NCT03531593
14 A Multicenter Study to Collect Samples for Future Evaluation of Biomarkers and Genetic Mutations in Patients Exposed to Adalimumab With Crohn's Disease (CD) or Ulcerative Colitis (UC) Who Developed Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT02087878
15 An Observational, Prospective, Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis Recruiting NCT02557308
16 An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Rheumatoid Arthritis Recruiting NCT02557295

Search NIH Clinical Center for Hepatosplenic T-Cell Lymphoma

Genetic Tests for Hepatosplenic T-Cell Lymphoma

Anatomical Context for Hepatosplenic T-Cell Lymphoma

MalaCards organs/tissues related to Hepatosplenic T-Cell Lymphoma:

41
Spleen, T Cells, Bone, Liver, Bone Marrow, B Cells, Nk Cells

Publications for Hepatosplenic T-Cell Lymphoma

Articles related to Hepatosplenic T-Cell Lymphoma:

(showing 247, show less)
# Title Authors PMID Year
1
Hepatosplenic T-Cell Lymphoma: A Rare Complication of Monotherapy with Thiopurines in Crohn's Disease. 38
31328143 2019
2
Tetrasomy 8 and isochromosome 7q in CD5-positive hepatosplenic T-cell lymphoma with leukemic presentation. 38
31342408 2019
3
Hepatosplenic αβ T-Cell Lymphoma as Second Malignancy in Young Adult Patient With Previously Undiagnosed Ataxia-Telangiectasia. 38
31259827 2019
4
Deregulated expression of NKL homeobox genes in T-cell lymphomas. 38
31143370 2019
5
Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review. 38
31362868 2019
6
Hepatosplenic T cell lymphoma presenting as multiorgan failure. 38
30902844 2019
7
DNA methylation profiling of hepatosplenic T-cell lymphoma. 38
30337361 2019
8
Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma. 38
30449784 2019
9
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. 38
31294385 2019
10
An unusual presentation of an uncommon lymphoma, hepatosplenic T-cell lymphoma. 38
30956608 2019
11
[Acute HIV infection pathologically mimicking T-cell lymphoma]. 38
31391369 2019
12
Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype. 38
31257346 2019
13
Hepatosplenic T-Cell Lymphomas. 38
30596219 2019
14
Case of a CD3 Negative Hepatosplenic T-Cell Lymphoma: Diagnostic and Therapeutic Challenges. 38
31346479 2019
15
Collapsing glomerulonephritis with podocyte markers in hemophagocytic syndrome secondary to hepatosplenic T-cell lymphoma 38
30653858 2018
16
Clinicopathological features of splenic tumours of lymphoid tissue. 38
30087035 2018
17
A rare case of hepatosplenic γδ T-cell lymphoma expressing CD19 with ring chromosome 7 and trisomy 8. 38
30553467 2018
18
Successful second allogeneic stem-cell transplantation from the same sibling donor for a patient with recurrent hepatosplenic gamma-delta (γ/δ) T-cell lymphoma: A case report. 38
30383643 2018
19
Hepatosplenic T-Cell Lymphoma in an Immunocompetent Male with Central Nervous System Invasion: A Rare Clinical Entity. 38
30500103 2018
20
Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction. 38
29766398 2018
21
Hepatosplenic γδ T Cell Lymphoma Involving the Brain. 38
30030187 2018
22
Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN. 38
29984520 2018
23
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma. 38
30153323 2018
24
Therapeutic role of methotrexate in pediatric Crohn's disease. 38
29338679 2018
25
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 1: PTCL-NOS, FTCL, AITL, ALCL. 38
30080923 2018
26
Hepatosplenic T-Cell Lymphoma Arising in a Patient Treated With Tumor Necrosis Factor-α Inhibitors for Ankylosing Spondylitis. 38
29933321 2018
27
[Incidence of Bone Marrow Involvement in Different Pathological Type Lymphoma Patients]. 38
29950217 2018
28
Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. 38
30082570 2018
29
Expect the unexpected - Loss of surface CD3 on flow cytometry in hepatosplenic T-cell lymphoma: An eye opener. 38
29676377 2018
30
Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. 38
29337025 2018
31
Intrasinusoidal pattern of bone marrow infiltration by hepatosplenic T-cell lymphoma. 38
29636955 2018
32
Leukemic conversion of hepatosplenic T-cell lymphoma with pleomorphic morphology and an aggressive course. 38
29676383 2018
33
Loss of CD3 and TCRγδ expression in a relapsed hepatosplenic T-cell lymphoma. 38
28573906 2018
34
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. 38
28822981 2017
35
[Tumors of lymphoid and hematopoietic tissue of spleen: a clinicopathologic analysis of 53 cases]. 38
29136691 2017
36
Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis. 38
28351190 2017
37
Hepatosplenic Gamma Delta T-Cell Lymphoma (HSGDTCL): Two Rare Case Reports from Western India. 38
29340126 2017
38
Florid splenic γ/δ T-cell proliferation in patients with splenomegaly and cytopenias: a "high stakes" diagnostic challenge. 38
28235627 2017
39
Leukemic phase of hepatosplenic T-cell lymphoma: A great masquerader of acute leukemia. 38
28937394 2017
40
Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States. 38
28263402 2017
41
It Takes a Village to Unmask HSTL. 38
28373165 2017
42
The Genetic Basis of Hepatosplenic T-cell Lymphoma. 38
28122867 2017
43
A Case of Hepatosplentic T Cell Lymphoma - A Rare, Aggressive Tumor of the Young. 38
28414669 2017
44
Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. 38
28038706 2017
45
Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience. 38
28222648 2017
46
T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report-Part 4. 38
28395105 2017
47
Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. 38
27755009 2017
48
Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy. 38
28058028 2016
49
Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease. 38
27811192 2016
50
Hepatosplenic T-cell lymphoma with coexistent hepatitis B infection: a rare clinicopathologic entity. 38
26481866 2016
51
Cutaneous presentation of hepatosplenic T-cell lymphoma-a potential mimicker of primary cutaneous gamma-delta T-cell lymphoma. 38
27562705 2016
52
Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis. 38
27516526 2016
53
Alopecia Areata as a Manifestation of Systemic Lymphoma: Report of Two Cases. 38
27843927 2016
54
Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. 38
27270301 2016
55
Hepatosplenic T Cell Lymphoma in an Immunocompetent Female Diagnosed using Flow Cytometry: A Rare Clinical Entity. 38
27656456 2016
56
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. 38
26872013 2016
57
Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents. 38
26992145 2016
58
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. 38
26997444 2016
59
Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. 38
26708981 2016
60
Hepatosplenic T-cell lymphoma in a young immunocompetent man. 38
27033291 2016
61
Cutaneous Involvement in a Case of Intravascular T-Cell Lymphoma With a γδ Phenotype. 38
26460624 2016
62
Four hepatosplenic T-cell lymphoma cases of Japanese patients. 38
26870659 2016
63
[Hepatosplenic T-cell lymphoma: The problems of diagnosis and treatment]. 38
28635923 2016
64
Hepatosplenic T-cell lymphoma: an acute leukemia presentation. 38
27158719 2016
65
Hepatosplenic T-cell lymphoma: an acute leukemia presentation 38
28845955 2016
66
Methotrexate for the Management of Crohn's Disease in Children. 38
26511908 2016
67
Monitoring for Extra-Intestinal Cancers in IBD. 38
26364836 2015
68
Hepatosplenic T-cell lymphoma with aberrant expression of serum β-HCG: a case report. 38
26108251 2015
69
Hepatosplenic T-cell lymphoma mimicking bone marrow metastasis. 38
26788568 2015
70
[Molecular pathogenesis of peripheral T-cell lymphoma (1): angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified and anaplastic large cell lymphoma]. 38
26481023 2015
71
Gastroenterology: Hepatosplenic T cell lymphoma associated with schistosomiasis. 38
26211690 2015
72
Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Review With an Emphasis on Diagnostic Differentiation From Other T-Cell/Natural Killer-Cell Neoplasms. 38
26317456 2015
73
Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. 38
26096944 2015
74
18F-FDG PET/CT in Hepatosplenic Gamma-Delta T-Cell Lymphoma. 38
26053728 2015
75
Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. 38
26047388 2015
76
Hepatosplenic T-cell lymphoma: A case series. 38
25450840 2015
77
Evaluation of the role of Epstein-Barr virus in cases of nodal or extranodal T- and NK-cell lymphoma using eber in situ hybridization. 38
26247530 2015
78
[Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation]. 38
26134007 2015
79
Childhood Hepatosplenic T-cell Lymphoma with Skin Involvement. 38
26061932 2015
80
Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. 38
25723615 2015
81
Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma. 38
25065703 2015
82
Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease. 38
27099586 2015
83
Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. 38
25234166 2015
84
Cancer and immunomodulators in inflammatory bowel diseases. 38
25545375 2015
85
The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. 38
25117775 2015
86
Zebras and hen's teeth: recognition and management of rare T and NK lymphomas. 38
26637770 2015
87
An Unusual Case of Hepatosplenic αβ T-Cell Lymphoma Presenting with Coombs'-Negative Hemolytic Anemia. 38
26688667 2015
88
Hemophagocytic lymphohistiocytosis associated with hepatosplenic T-cell lymphoma: case report. 38
28573125 2014
89
Hepatosplenic T cell lymphoma. 38
25332524 2014
90
Hepatosplenic T cell lymphoma: a rare case report. 38
25332523 2014
91
Hepatosplenic T-cell lymphoma: a rare cause of hepatosplenomegaly. 38
25012882 2014
92
De novo CD3 negative hepatosplenic T-cell lymphoma: diagnostic challenges and pitfalls. 38
24978925 2014
93
Hepatosplenic T-cell lymphoma. 38
25221804 2014
94
Lymphoma with features intermediate between aggressive T-large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma: a diagnostic dilemma? 38
24524924 2014
95
Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis. 38
24761381 2014
96
Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? 38
24621284 2014
97
[Hemophacocytic syndrome as early sign for hepatosplenic T-cell lymphoma in a patient with chronic lymphocytic leukaemia]. 38
24736146 2014
98
Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. 38
24621139 2014
99
Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. 38
24374875 2014
100
Allogeneic transplantation in T-cell lymphomas. 38
24468318 2014
101
Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. 38
25057852 2014
102
Purpura of the face and neck: an atypical clinical presentation revealing a hepatosplenic T cell lymphoma. 38
24707248 2014
103
Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha/beta (αβ) T-cell lymphoma. 38
25429355 2014
104
Hepatosplenic gamma delta T-cell lymphoma in a boy with visceral leishmaniasis: a case report. 38
24330681 2013
105
Hepatosplenic T-cell lymphoma. 38
24033076 2013
106
Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. 38
23402267 2013
107
CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma. 38
23800602 2013
108
Hepatosplenic T-cell lymphoma appearing in the peripheral blood. 38
24137640 2013
109
Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma. 38
23826928 2013
110
Risk of lymphoma subtypes after solid organ transplantation in the United States. 38
23756857 2013
111
Intestinal γδ T-cell lymphomas are most frequently of type II enteropathy-associated T-cell type. 38
23332928 2013
112
Hepatosplenic alpha/beta T-cell lymphoma masquerading as cirrhosis. 38
23730508 2013
113
Do inflammatory bowel disease therapies cause cancer? 38
23470503 2013
114
Primary T-cell lymphoma of liver. 38
23608840 2013
115
Hepatosplenic and hepatocytotropic T-cell lymphoma: two distinct types of T-cell lymphoma in dogs. 38
22711745 2013
116
Hepatosplenic T-cell lymphoma: is cure possible? 38
23598915 2013
117
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. 38
23107915 2013
118
Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. 38
23296147 2013
119
Successful treatment of hepatosplenic T-cell lymphoma with ESHAP followed by autologous stem cell transplant. 38
23598914 2013
120
Histopathological, immunophenotypic and clinical particularities and evolution of a case of hepatosplenic T-cell lymphoma in transformation to leukemia. 38
24399013 2013
121
Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. 38
23281437 2013
122
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. 38
23032984 2013
123
Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. 38
23094824 2013
124
Peripheral T-cell lymphoma in children and adolescents: a single-institution experience. 38
23042011 2012
125
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. 38
22770877 2012
126
[Lymphomas and lymphatic leukemias in the bone marrow]. 38
23085695 2012
127
Peripheral T-cell lymphoma: frequency and distribution in a tertiary referral center in South India. 38
23455774 2012
128
Effectiveness and safety of minilaparoscopy-guided spleen biopsy: a retrospective series of 57 cases. 38
22350241 2012
129
Hepatosplenic gamma-delta T-cell lymphoma. 38
22047938 2012
130
Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. 38
22510872 2012
131
Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India. 38
21916832 2012
132
Differential diagnosis of CD4-/CD8- γδ T-cell large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma. 38
22338065 2012
133
F-18 Fluorodeoxyglucose non-avid hepatosplenic T cell lymphoma: a diagnostic pitfall. 38
21584668 2012
134
Hematologic features of hepatosplenic T-cell lymphoma. 38
22261460 2012
135
Lymphoma-like T cell infiltration in liver is associated with increased copy number of dominant negative form of TGFβ receptor II. 38
23145171 2012
136
The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. 38
21823196 2012
137
[Enteropathy-associated intestinal t-cell lymphoma without celiac disease]. 38
22177267 2012
138
Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented? 38
22796808 2012
139
F-18 flourodeoxyglucose positron emission tomography/computed tomography findings in a case of hepatosplenic T-cell lymphoma. 38
22531524 2012
140
Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases. 38
21683978 2011
141
Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii. 38
22362328 2011
142
Relapsed hepatosplenic T-cell lymphoma heralded by a solitary skin nodule. 38
21752051 2011
143
Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. 38
21941193 2011
144
[Inflammatory bowel disease and lymphoproliferative disorders]. 38
22042416 2011
145
Hepatosplenic T-cell lymphoma is a distinct rare entity: diagnosis by fine-needle aspiration cytology. 38
21837655 2011
146
Hepatic failure and death due to new onset T cell lymphoma. 38
20512458 2011
147
Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia. 38
21757603 2011
148
Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system. 38
21663333 2011
149
Hepatosplenic T-cell lymphoma. 38
22379294 2011
150
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. 38
21052088 2011
151
Cytogenetic and molecular characterization of a hepatosplenic T-cell lymphoma: report of a novel chromosomal aberration. 38
21504708 2011
152
A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. 38
20888436 2011
153
Common variable immunodeficiency associated with hepatosplenic T-cell lymphoma mimicking juvenile systemic lupus erythematosus. 38
21776287 2011
154
Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. 38
21122582 2010
155
Hepatosplenic T-cell lymphoma and inflammatory bowel disease. 38
21122554 2010
156
Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. 38
20927075 2010
157
Hepatosplenic T cell lymphoma responsive to 2'-deoxycoformycin therapy. 38
20652973 2010
158
Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. 38
20594135 2010
159
A seventeen-year-old female with hepatosplenic T-cell lymphoma associated with parvoviral infection. 38
21589836 2010
160
Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. 38
20371449 2010
161
Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? 38
20210767 2010
162
Biology and management of rare primary extranodal T-cell lymphomas. 38
20187328 2010
163
Hepatosplenic T-cell lymphoma and TNF-α inhibitors. 38
21082951 2009
164
Gamma-delta T-cell lymphomas. 38
19901919 2009
165
Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant. 38
19479793 2009
166
Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. 38
19749141 2009
167
Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails? 38
20028325 2009
168
Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree? 38
19067412 2009
169
Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia. 38
19408055 2009
170
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. 38
19575026 2009
171
T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. 38
19669196 2009
172
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. 38
19237479 2009
173
[Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab]. 38
19409244 2009
174
Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients? 38
19192165 2009
175
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. 38
19274799 2009
176
Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. 38
19296822 2009
177
Serum sickness, encephalitis and other complications of anti-cytokine therapy. 38
19258190 2009
178
Hepatosplenic T cell lymphoma in inflammatory bowel disease. 38
18667489 2008
179
Erythrophagocytic low-grade extranodal T-cell lymphoma in a cat. 38
19055577 2008
180
Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. 38
18928444 2008
181
Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. 38
18628085 2008
182
[Clinicopathologic study of hepatosplenic T-cell lymphoma]. 38
18677385 2008
183
Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha. 38
18452073 2008
184
Pituitary gland involvement by a gamma delta hepatosplenic lymphoma, a mimicker of pituitary adenoma: report of a rare case. 38
18317685 2008
185
Malignant lymphoma without lymphadenopathy. 38
18700647 2008
186
Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. 38
17876769 2008
187
Submassive hepatocellular necrosis associated with infiltration by peripheral T-cell lymphoma of cytotoxic phenotype: report of two cases. 38
18199164 2008
188
Infliximab therapy for pediatric Crohn's disease. 38
18034652 2007
189
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? 38
17480018 2007
190
[Dermatomyositis associated with hepatosplenic gamma delta T-cell lymphoma]. 38
17559983 2007
191
[Retrospective analysis of 54 patients with high risk aggressive T-cell non-Hodgkin lymphomas]. 38
18072627 2007
192
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. 38
17613771 2007
193
Hepatosplenic and other gammadelta T-cell lymphomas. 38
17509984 2007
194
T-cell and NK-cell posttransplantation lymphoproliferative disorders. 38
17509986 2007
195
[Splenic T-cell and NK-cell lymphomas: a clinicopathologic and immunophenotypic analysis of 9 cases]. 38
17877195 2007
196
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. 38
17255842 2007
197
Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. 38
17255825 2007
198
Infliximab therapy in children and adolescents with inflammatory bowel disease. 38
17683171 2007
199
Hepatosplenic gammadelta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration. 38
16941150 2006
200
Ring chromosome 7 with amplification of 7q sequences in a pediatric case of hepatosplenic T-cell lymphoma. 38
16737917 2006
201
NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. 38
16525496 2006
202
[Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report]. 38
16808095 2006
203
Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone. 38
16321867 2006
204
Progressive multifocal leukoencephalopathy in a patient with hepatosplenic T cell lymphoma. 38
16479120 2006
205
Isochromosome 7q in Down syndrome. 38
16434320 2006
206
Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. 38
16914902 2006
207
Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations. 38
16507204 2006
208
Pathobiology of peripheral T-cell lymphomas. 38
17124078 2006
209
[Disseminated infections due to Scedosporium apiospermum in a patient with anaplastic large cell lymphoma. A case study]. 38
16607764 2005
210
Hepatosplenic gammadelta T-cell lymphoma. 38
15968729 2005
211
Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. 38
15699701 2005
212
Clinicopathological features of eight Korean cases of primary hepatic lymphoma. 38
15533225 2004
213
Case report: a common presentation of a rare disease-hepatosplenic T-cell lymphoma. 38
15633661 2004
214
Bone marrow histopathology in peripheral T-cell lymphomas. 38
15461619 2004
215
Treatment of T-cell non-Hodgkin's lymphoma. 38
15233906 2004
216
[Hepatosplenic gammadeltaT-cell lymphoma: a clinicopathological study]. 38
14724108 2004
217
Morphologic, immunohistochemical, and molecular characterization of hepatosplenic T-cell lymphoma in a dog. 38
15195270 2004
218
Hepatosplenic T cell lymphoma with no expression of cytotoxic molecules. 38
12890821 2003
219
Gammadelta T-cell lymphomas. 38
12876672 2003
220
Classification of cytotoxic T-cell and natural killer cell lymphomas. 38
12876666 2003
221
Hepato-splenic lymphoma: a rare entity mimicking acute hepatitis: a case report. 38
12800262 2003
222
Hematologic malignancies with extramedullary spread of disease. Case 2. Hepatosplenic T-cell lymphoma. 38
12721269 2003
223
Splenic involvement by peripheral T-cell and NK-cell neoplasms. 38
12945934 2003
224
Hepatosplenic alpha beta T-cell lymphoma: a report of an S100-positive case. 38
12653597 2003
225
[Classification and differential diagnosis of NK/T-cell lymphomas]. 38
16888893 2003
226
Molecular etiology of mature T-cell non-Hodgkin's lymphomas. 38
12456315 2003
227
Intrasinusoidal bone marrow infiltration: a common growth pattern for different lymphoma subtypes. 38
12472568 2002
228
Hepatosplenic T-cell lymphoma in a mare. 38
12126157 2002
229
Hepatosplenic gammadelta T-cell lymphoma presenting with immune-mediated thrombocytopenia and hemolytic anemia (Evans' syndrome). 38
11921021 2002
230
Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. 38
11807981 2002
231
Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. 38
11554170 2001
232
Hepatosplenic T-cell lymphoma. 38
11472337 2001
233
Hepatosplenic T-cell lymphoma of alphabeta lineage. 38
11420473 2001
234
Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. 38
10895827 2000
235
Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. 38
10865963 2000
236
gammadelta T-cell lymphomas: a homogeneous entity? 38
10759943 2000
237
Hepatosplenic T-cell lymphoma of alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia. 38
10716161 2000
238
CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma. 38
9511938 1998
239
Hepatosplenic T-cell lymphoma: prolymphocytic transformation 18 months after splenectomy. 38
9277054 1997
240
Cytotoxic T-lymphocyte differentiation and cytogenetic alterations in gammadelta hepatosplenic T-cell lymphoma and posttransplant lymphoproliferative disorders. 38
9129060 1997
241
Hepatosplenic T-cell lymphoma: sinusoidal localization of malignant T-cells--a case report. 38
8948673 1996
242
Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. 38
8943863 1996
243
Aggressive primary hepatic lymphoma in Chinese patients. Presentation, pathologic features, and outcome. 38
8620406 1995
244
Hepatosplenic T-cell lymphoma: an unusual case of a gamma delta T-cell lymphoma with a blast-like terminal transformation. 38
8314255 1994
245
Malignant lymphoma imitating hepatitis. 38
8453587 1993
246
Bone marrow histologic and immunohistochemical findings in peripheral. T-cell lymphoma: A study of 38 cases. 38
2050367 1991
247
Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. 38
2140703 1990

Variations for Hepatosplenic T-Cell Lymphoma

Expression for Hepatosplenic T-Cell Lymphoma

LifeMap Discovery
Genes differentially expressed in tissues of Hepatosplenic T-Cell Lymphoma patients vs. healthy controls: 35 (showing 400, show less)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TMEM178A transmembrane protein 178A Spleen + 9.71 0.000
2 LPAR3 lysophosphatidic acid receptor 3 Spleen + 8.91 0.000
3 SOX2 SRY (sex determining region Y)-box 2 Spleen + 8.60 0.000
4 MLC1 megalencephalic leukoencephalopathy with subcortical cysts 1 Spleen + 7.68 0.001
5 CLEC3B C-type lectin domain family 3, member B Spleen - 7.16 0.001
6 KIR2DS1 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1 Spleen + 7.16 0.000
7 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 Spleen - 7.01 0.023
8 KIR3DL1 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 Spleen + 6.95 0.000
9 KIR3DS1 killer cell immunoglobulin-like receptor, three domains, short cytoplasmic tail, 1 Spleen + 6.85 0.001
10 ADAMTS17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 Spleen + 6.83 0.000
11 KIR3DL3 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 3 Spleen + 6.66 0.000
12 KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 Spleen + 6.63 0.001
13 MARCO macrophage receptor with collagenous structure Spleen + 6.61 0.009
14 KIR2DS3 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3 Spleen + 6.34 0.001
15 CXCL13 chemokine (C-X-C motif) ligand 13 Spleen - 6.26 0.004
16 OLFML2A olfactomedin-like 2A Spleen - 6.25 0.015
17 KIR2DL2 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2 Spleen + 6.21 0.002
18 KIR2DS2 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 Spleen + 6.14 0.000
19 KIR2DS4 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 4 Spleen + 6.13 0.001
20 GREB1 growth regulation by estrogen in breast cancer 1 Spleen + 6.09 0.001
21 KIR2DL1 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1 Spleen + 6.02 0.002
22 LOC100505501 uncharacterized LOC100505501 Spleen + 5.96 0.000
23 MAATS1 MYCBP-associated, testis expressed 1 Spleen - 5.93 0.000
24 TRGV5 T cell receptor gamma variable 5 Spleen + 5.90 0.000
25 CRHBP corticotropin releasing hormone binding protein Spleen - 5.89 0.000
26 KLRC3 killer cell lectin-like receptor subfamily C, member 3 Spleen + 5.87 0.000
27 SMIM24 small integral membrane protein 24 Spleen + 5.85 0.000
28 CCM2L cerebral cavernous malformation 2-like Spleen - 5.83 0.005
29 RUNDC3B RUN domain containing 3B Spleen + 5.82 0.000
30 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 Spleen + 5.80 0.000
31 PCDH7 protocadherin 7 Spleen - 5.78 0.010
32 APLNR apelin receptor Spleen - 5.76 0.000
33 KIR2DL5A killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5A Spleen + 5.73 0.001
34 KIR2DS5 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5 Spleen + 5.69 0.001
35 GIPC2 GIPC PDZ domain containing family, member 2 Spleen - 5.69 0.000
36 GTSF1 gametocyte specific factor 1 Spleen + 5.62 0.001
37 GPM6A glycoprotein M6A Spleen - 5.62 0.000
38 IGFBP3 insulin-like growth factor binding protein 3 Spleen - 5.61 0.004
39 BMP7 bone morphogenetic protein 7 Spleen + 5.59 0.000
40 PDE2A phosphodiesterase 2A, cGMP-stimulated Spleen - 5.58 0.002
41 KIF14 kinesin family member 14 Spleen + 5.55 0.000
42 HYAL1 hyaluronoglucosaminidase 1 Spleen - 5.51 0.006
43 GPR82 G protein-coupled receptor 82 Spleen + 5.49 0.000
44 DNASE1L3 deoxyribonuclease I-like 3 Spleen - 5.44 0.003
45 USP44 ubiquitin specific peptidase 44 Spleen + 5.44 0.000
46 CD96 CD96 molecule Spleen + 5.42 0.001
47 AKAP5 A kinase (PRKA) anchor protein 5 Spleen + 5.41 0.000
48 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) Spleen - 5.40 0.008
49 PLVAP plasmalemma vesicle associated protein Spleen - 5.38 0.001
50 NEK2 NIMA-related kinase 2 Spleen + 5.35 0.000
51 KCNAB1 potassium channel, voltage gated subfamily A regulatory beta subunit 1 Spleen - 5.29 0.000
52 HCAR3 hydroxycarboxylic acid receptor 3 Spleen - 5.29 0.006
53 CHODL chondrolectin Spleen - 5.28 0.001
54 GBA3 glucosidase, beta, acid 3 (gene/pseudogene) Spleen - 5.25 0.000
55 NCAM1 neural cell adhesion molecule 1 Spleen + 5.19 0.003
56 PBK PDZ binding kinase Spleen + 5.16 0.000
57 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Spleen + 5.13 0.001
58 HSPB8 heat shock 22kDa protein 8 Spleen - 5.11 0.002
59 PITPNM3 PITPNM family member 3 Spleen - 5.09 0.010
60 CHMP4C charged multivesicular body protein 4C Spleen - 5.09 0.000
61 PTX3 pentraxin 3, long Spleen - 5.07 0.012
62 KIF20A kinesin family member 20A Spleen + 5.05 0.000
63 FAM110B family with sequence similarity 110, member B Spleen - 5.04 0.005
64 SDPR serum deprivation response Spleen - 5.03 0.012
65 BIRC5 baculoviral IAP repeat containing 5 Spleen + 5.02 0.000
66 LIMCH1 LIM and calponin homology domains 1 Spleen - 4.99 0.006
67 CENPF centromere protein F, 350/400kDa Spleen + 4.98 0.000
68 TOP2A topoisomerase (DNA) II alpha Spleen + 4.98 0.000
69 KIAA0101 KIAA0101 Spleen + 4.98 0.000
70 ZNF521 zinc finger protein 521 Spleen - 4.96 0.004
71 KIF2C kinesin family member 2C Spleen + 4.95 0.000
72 ASPM abnormal spindle microtubule assembly Spleen + 4.94 0.001
73 TSPAN12 tetraspanin 12 Spleen - 4.93 0.006
74 TEK TEK tyrosine kinase, endothelial Spleen - 4.92 0.021
75 SLCO4C1 solute carrier organic anion transporter family, member 4C1 Spleen + 4.91 0.001
76 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Spleen + 4.89 0.001
77 SEPP1 selenoprotein P, plasma, 1 Spleen - 4.89 0.000
78 CD79A CD79a molecule, immunoglobulin-associated alpha Spleen - 4.89 0.039
79 ST6GALNAC1 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 Spleen - 4.85 0.000
80 ADAMDEC1 ADAM-like, decysin 1 Spleen - 4.85 0.008
81 UHRF1 ubiquitin-like with PHD and ring finger domains 1 Spleen + 4.84 0.000
82 FLRT3 fibronectin leucine rich transmembrane protein 3 Spleen + 4.82 0.012
83 PCDH17 protocadherin 17 Spleen - 4.82 0.041
84 BLNK B-cell linker Spleen - 4.81 0.036
85 SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 Spleen - 4.80 0.004
86 CDKN3 cyclin-dependent kinase inhibitor 3 Spleen + 4.80 0.001
87 DSP desmoplakin Spleen - 4.79 0.000
88 STAB2 stabilin 2 Spleen - 4.74 0.022
89 TPX2 TPX2, microtubule-associated Spleen + 4.73 0.000
90 KCNQ5 potassium channel, voltage gated KQT-like subfamily Q, member 5 Spleen + 4.73 0.000
91 CFI complement factor I Spleen - 4.72 0.025
92 CENPA centromere protein A Spleen + 4.70 0.001
93 PDGFD platelet derived growth factor D Spleen + 4.69 0.000
94 TK1 thymidine kinase 1, soluble Spleen + 4.67 0.000
95 CENPE centromere protein E, 312kDa Spleen + 4.66 0.000
96 FCRLB Fc receptor-like B Spleen + 4.66 0.001
97 HOMER3 homer scaffolding protein 3 Spleen - 4.65 0.022
98 KIF18B kinesin family member 18B Spleen + 4.65 0.001
99 NKX2-3 NK2 homeobox 3 Spleen - 4.64 0.026
100 GDPD2 glycerophosphodiester phosphodiesterase domain containing 2 Spleen - 4.64 0.000
101 DEPDC1 DEP domain containing 1 Spleen + 4.63 0.000
102 TARP TCR gamma alternate reading frame protein Spleen + 4.63 0.000
103 PTPRB protein tyrosine phosphatase, receptor type, B Spleen - 4.61 0.013
104 KLF4 Kruppel-like factor 4 (gut) Spleen - 4.60 0.011
105 TMSB15A thymosin beta 15a Spleen + 4.60 0.002
106 AXL AXL receptor tyrosine kinase Spleen - 4.60 0.001
107 SIRPG signal-regulatory protein gamma Spleen + 4.59 0.000
108 MIB2 mindbomb E3 ubiquitin protein ligase 2 Spleen + 4.59 0.000
109 CNTN1 contactin 1 Spleen - 4.59 0.000
110 E2F7 E2F transcription factor 7 Spleen + 4.59 0.000
111 CYYR1 cysteine/tyrosine-rich 1 Spleen - 4.58 0.002
112 KAZN kazrin, periplakin interacting protein Spleen - 4.57 0.003
113 EPHA7 EPH receptor A7 Spleen - 4.56 0.000
114 GINS2 GINS complex subunit 2 (Psf2 homolog) Spleen + 4.56 0.000
115 DEPDC1B DEP domain containing 1B Spleen + 4.55 0.000
116 NUF2 NUF2, NDC80 kinetochore complex component Spleen + 4.55 0.000
117 ADIRF adipogenesis regulatory factor Spleen - 4.55 0.008
118 CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) Spleen - 4.55 0.015
119 FAM83D family with sequence similarity 83, member D Spleen + 4.54 0.000
120 TYMS thymidylate synthetase Spleen + 4.53 0.000
121 FOXM1 forkhead box M1 Spleen + 4.53 0.000
122 C1orf115 chromosome 1 open reading frame 115 Spleen - 4.52 0.007
123 TCL1A T-cell leukemia/lymphoma 1A Spleen - 4.52 0.024
124 UBE2C ubiquitin-conjugating enzyme E2C Spleen + 4.52 0.000
125 THBD thrombomodulin Spleen - 4.51 0.022
126 S100B S100 calcium binding protein B Spleen + 4.50 0.022
127 MKI67 marker of proliferation Ki-67 Spleen + 4.50 0.000
128 ARHGEF40 Rho guanine nucleotide exchange factor (GEF) 40 Spleen - 4.49 0.000
129 GPR183 G protein-coupled receptor 183 Spleen - 4.48 0.012
130 KIF15 kinesin family member 15 Spleen + 4.48 0.001
131 CD163L1 CD163 molecule-like 1 Spleen - 4.47 0.001
132 ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Spleen + 4.47 0.000
133 NOS3 nitric oxide synthase 3 (endothelial cell) Spleen - 4.47 0.021
134 OIP5 Opa interacting protein 5 Spleen + 4.46 0.000
135 SLC16A9 solute carrier family 16, member 9 Spleen - 4.46 0.010
136 CEP55 centrosomal protein 55kDa Spleen + 4.46 0.000
137 ROBO4 roundabout guidance receptor 4 Spleen - 4.46 0.007
138 CXCL12 chemokine (C-X-C motif) ligand 12 Spleen - 4.44 0.011
139 LGR4 leucine-rich repeat containing G protein-coupled receptor 4 Spleen - 4.44 0.000
140 THRB thyroid hormone receptor, beta Spleen - 4.43 0.000
141 MYCT1 myc target 1 Spleen - 4.43 0.010
142 E2F8 E2F transcription factor 8 Spleen + 4.42 0.000
143 TMEM200A transmembrane protein 200A Spleen + 4.42 0.002
144 AIF1L allograft inflammatory factor 1-like Spleen - 4.42 0.029
145 PSD3 pleckstrin and Sec7 domain containing 3 Spleen - 4.42 0.005
146 NDRG2 NDRG family member 2 Spleen - 4.41 0.006
147 CCNB2 cyclin B2 Spleen + 4.40 0.001
148 EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) Spleen - 4.39 0.019
149 NDRG4 NDRG family member 4 Spleen - 4.39 0.000
150 MCM10 minichromosome maintenance 10 replication initiation factor Spleen + 4.39 0.000
151 TOX thymocyte selection-associated high mobility group box Spleen + 4.36 0.001
152 APOE apolipoprotein E Spleen - 4.36 0.016
153 HJURP Holliday junction recognition protein Spleen + 4.36 0.000
154 CHSY3 chondroitin sulfate synthase 3 Spleen + 4.36 0.000
155 CCL24 chemokine (C-C motif) ligand 24 Spleen - 4.36 0.001
156 MET MET proto-oncogene, receptor tyrosine kinase Spleen - 4.35 0.001
157 CDCA7 cell division cycle associated 7 Spleen + 4.34 0.001
158 VWF von Willebrand factor Spleen - 4.34 0.021
159 ARHGAP28 Rho GTPase activating protein 28 Spleen - 4.34 0.014
160 PRC1 protein regulator of cytokinesis 1 Spleen + 4.34 0.000
161 IGHD immunoglobulin heavy constant delta Spleen - 4.34 0.012
162 MGP matrix Gla protein Spleen - 4.34 0.010
163 CHST9 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 Spleen - 4.34 0.000
164 RTN1 reticulon 1 Spleen - 4.33 0.035
165 SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) Spleen + 4.33 0.006
166 FAM179A family with sequence similarity 179, member A Spleen + 4.32 0.001
167 MYRIP myosin VIIA and Rab interacting protein Spleen - 4.32 0.004
168 EFHD1 EF-hand domain family, member D1 Spleen - 4.32 0.023
169 TSPAN7 tetraspanin 7 Spleen - 4.31 0.017
170 CPB1 carboxypeptidase B1 (tissue) Spleen - 4.31 0.000
171 FCRLA Fc receptor-like A Spleen - 4.29 0.027
172 FPR3 formyl peptide receptor 3 Spleen - 4.29 0.019
173 KIR2DL4 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 Spleen + 4.29 0.009
174 CCNA2 cyclin A2 Spleen + 4.28 0.000
175 SHANK3 SH3 and multiple ankyrin repeat domains 3 Spleen - 4.27 0.011
176 CD22 CD22 molecule Spleen - 4.27 0.023
177 FXYD6 FXYD domain containing ion transport regulator 6 Spleen - 4.27 0.026
178 EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit Spleen + 4.27 0.000
179 ANLN anillin actin binding protein Spleen + 4.26 0.000
180 NUDT11 nudix (nucleoside diphosphate linked moiety X)-type motif 11 Spleen + 4.25 0.010
181 NUSAP1 nucleolar and spindle associated protein 1 Spleen + 4.25 0.000
182 AURKB aurora kinase B Spleen + 4.24 0.000
183 CAV1 caveolin 1, caveolae protein, 22kDa Spleen - 4.22 0.017
184 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Spleen + 4.21 0.000
185 FASLG Fas ligand (TNF superfamily, member 6) Spleen + 4.21 0.000
186 PLEKHG1 pleckstrin homology domain containing, family G (with RhoGef domain) member 1 Spleen - 4.20 0.005
187 CDC20 cell division cycle 20 Spleen + 4.20 0.003
188 INSR insulin receptor Spleen - 4.20 0.020
189 C8orf4 chromosome 8 open reading frame 4 Spleen - 4.20 0.015
190 CNTN3 contactin 3 (plasmacytoma associated) Spleen - 4.20 0.000
191 CD247 CD247 molecule Spleen + 4.19 0.000
192 EPPK1 epiplakin 1 Spleen - 4.19 0.001
193 PRSS21 protease, serine, 21 (testisin) Spleen + 4.19 0.000
194 NOG noggin Spleen + 4.18 0.033
195 CDCA2 cell division cycle associated 2 Spleen + 4.18 0.000
196 GTSE1 G-2 and S-phase expressed 1 Spleen + 4.18 0.001
197 SH2D2A SH2 domain containing 2A Spleen + 4.17 0.000
198 FLJ35700 uncharacterized protein FLJ35700 Spleen - 4.17 0.008
199 RRM2 ribonucleotide reductase M2 Spleen + 4.16 0.001
200 C2orf40 chromosome 2 open reading frame 40 Spleen - 4.15 0.032
201 MELK maternal embryonic leucine zipper kinase Spleen + 4.15 0.000
202 CASC5 cancer susceptibility candidate 5 Spleen + 4.15 0.000
203 PAX5 paired box 5 Spleen - 4.14 0.044
204 LILRB5 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5 Spleen - 4.14 0.017
205 CCNB1 cyclin B1 Spleen + 4.13 0.001
206 SLC4A4 solute carrier family 4 (sodium bicarbonate cotransporter), member 4 Spleen + 4.13 0.009
207 ADGRF5 adhesion G protein-coupled receptor F5 Spleen - 4.13 0.046
208 KLHL14 kelch-like family member 14 Spleen - 4.12 0.038
209 VPREB3 pre-B lymphocyte 3 Spleen - 4.12 0.018
210 MEST mesoderm specific transcript Spleen - 4.11 0.006
211 ERG v-ets avian erythroblastosis virus E26 oncogene homolog Spleen - 4.11 0.009
212 KLRC4 killer cell lectin-like receptor subfamily C, member 4 Spleen + 4.10 0.028
213 NCAPG non-SMC condensin I complex, subunit G Spleen + 4.10 0.000
214 NR4A2 nuclear receptor subfamily 4, group A, member 2 Spleen + 4.10 0.045
215 CCNE2 cyclin E2 Spleen + 4.10 0.000
216 TM4SF18 transmembrane 4 L six family member 18 Spleen - 4.09 0.035
217 BRIP1 BRCA1 interacting protein C-terminal helicase 1 Spleen + 4.09 0.000
218 IGF1 insulin-like growth factor 1 (somatomedin C) Spleen - 4.08 0.001
219 FCRL2 Fc receptor-like 2 Spleen - 4.08 0.013
220 HMMR hyaluronan-mediated motility receptor (RHAMM) Spleen + 4.07 0.001
221 TMEM150C transmembrane protein 150C Spleen - 4.07 0.007
222 ITGA1 integrin, alpha 1 Spleen - 4.07 0.048
223 NELL2 neural EGFL like 2 Spleen + 4.06 0.006
224 NTN4 netrin 4 Spleen - 4.06 0.016
225 CAV2 caveolin 2 Spleen - 4.06 0.014
226 CKAP2L cytoskeleton associated protein 2-like Spleen + 4.05 0.000
227 CDK1 cyclin-dependent kinase 1 Spleen + 4.05 0.000
228 LY86 lymphocyte antigen 86 Spleen - 4.05 0.007
229 CDT1 chromatin licensing and DNA replication factor 1 Spleen + 4.05 0.000
230 RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 Spleen - 4.05 0.003
231 C3orf70 chromosome 3 open reading frame 70 Spleen - 4.04 0.001
232 SPAG5 sperm associated antigen 5 Spleen + 4.03 0.000
233 APBA2 amyloid beta (A4) precursor protein-binding, family A, member 2 Spleen + 4.03 0.001
234 TRIM2 tripartite motif containing 2 Spleen - 4.03 0.010
235 ERAP2 endoplasmic reticulum aminopeptidase 2 Spleen - 4.02 0.000
236 NMU neuromedin U Spleen + 4.02 0.022
237 KLRD1 killer cell lectin-like receptor subfamily D, member 1 Spleen + 4.02 0.000
238 TTK TTK protein kinase Spleen + 4.01 0.000
239 RAMP1 receptor (G protein-coupled) activity modifying protein 1 Spleen + 4.01 0.012
240 FCRL1 Fc receptor-like 1 Spleen - 4.01 0.006
241 ETS2 v-ets avian erythroblastosis virus E26 oncogene homolog 2 Spleen - 4.00 0.007
242 CRTAM cytotoxic and regulatory T cell molecule Spleen + 4.00 0.000
243 LIFR leukemia inhibitory factor receptor alpha Spleen - 4.00 0.049
244 TREM1 triggering receptor expressed on myeloid cells 1 Spleen - 3.99 0.000
245 MOB3B MOB kinase activator 3B Spleen - 3.99 0.027
246 LRP4 low density lipoprotein receptor-related protein 4 Spleen - 3.99 0.000
247 STOX2 storkhead box 2 Spleen - 3.99 0.001
248 CHEK1 checkpoint kinase 1 Spleen + 3.99 0.000
249 ACKR1 atypical chemokine receptor 1 (Duffy blood group) Spleen - 3.98 0.015
250 FABP3 fatty acid binding protein 3, muscle and heart Spleen - 3.98 0.015
251 MMRN2 multimerin 2 Spleen - 3.98 0.005
252 AGTR1 angiotensin II receptor, type 1 Spleen - 3.97 0.013
253 GNLY granulysin Spleen - 3.97 0.038
254 EBF1 early B-cell factor 1 Spleen - 3.96 0.011
255 SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 Spleen - 3.95 0.008
256 MCM4 minichromosome maintenance complex component 4 Spleen + 3.94 0.000
257 TMTC1 transmembrane and tetratricopeptide repeat containing 1 Spleen - 3.94 0.039
258 KIF11 kinesin family member 11 Spleen + 3.94 0.000
259 LGALS2 lectin, galactoside-binding, soluble, 2 Spleen - 3.93 0.004
260 PLK2 polo-like kinase 2 Spleen - 3.92 0.012
261 TRD T cell receptor delta locus Spleen + 3.92 0.024
262 IGSF21 immunoglobin superfamily, member 21 Spleen - 3.92 0.000
263 S1PR5 sphingosine-1-phosphate receptor 5 Spleen + 3.92 0.006
264 PCSK6 proprotein convertase subtilisin/kexin type 6 Spleen - 3.91 0.005
265 SEMA3D sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D Spleen - 3.91 0.007
266 PHGDH phosphoglycerate dehydrogenase Spleen + 3.91 0.008
267 GAPT GRB2-binding adaptor protein, transmembrane Spleen - 3.90 0.026
268 SPIB Spi-B transcription factor (Spi-1/PU.1 related) Spleen - 3.90 0.016
269 CDC6 cell division cycle 6 Spleen + 3.90 0.001
270 UBE2T ubiquitin-conjugating enzyme E2T Spleen + 3.89 0.000
271 RMI2 RecQ mediated genome instability 2 Spleen + 3.88 0.000
272 ENTPD3 ectonucleoside triphosphate diphosphohydrolase 3 Spleen - 3.88 0.000
273 BLK BLK proto-oncogene, Src family tyrosine kinase Spleen - 3.87 0.004
274 FGD5 FYVE, RhoGEF and PH domain containing 5 Spleen - 3.87 0.004
275 ELOVL6 ELOVL fatty acid elongase 6 Spleen + 3.86 0.004
276 NCAPH non-SMC condensin I complex, subunit H Spleen + 3.86 0.000
277 HOMER1 homer scaffolding protein 1 Spleen + 3.85 0.002
278 ITGAD integrin, alpha D Spleen + 3.85 0.001
279 ARHGAP29 Rho GTPase activating protein 29 Spleen - 3.84 0.023
280 MPPED2 metallophosphoesterase domain containing 2 Spleen - 3.84 0.004
281 ADGRL4 adhesion G protein-coupled receptor L4 Spleen - 3.83 0.050
282 CCL19 chemokine (C-C motif) ligand 19 Spleen - 3.83 0.037
283 NAV3 neuron navigator 3 Spleen - 3.83 0.001
284 NRP1 neuropilin 1 Spleen - 3.83 0.034
285 HLA-DOB major histocompatibility complex, class II, DO beta Spleen - 3.82 0.034
286 PROX1 prospero homeobox 1 Spleen - 3.82 0.003
287 CDCA8 cell division cycle associated 8 Spleen + 3.82 0.000
288 RORB RAR-related orphan receptor B Spleen + 3.81 0.004
289 CDCA5 cell division cycle associated 5 Spleen + 3.81 0.000
290 CES1 carboxylesterase 1 Spleen - 3.81 0.017
291 ASB9 ankyrin repeat and SOCS box containing 9 Spleen - 3.81 0.000
292 MYH11 myosin, heavy chain 11, smooth muscle Spleen - 3.79 0.027
293 SPC25 SPC25, NDC80 kinetochore complex component Spleen + 3.79 0.000
294 PLPP3 phospholipid phosphatase 3 Spleen - 3.79 0.024
295 JAKMIP2 janus kinase and microtubule interacting protein 2 Spleen + 3.79 0.003
296 ATAD2 ATPase family, AAA domain containing 2 Spleen + 3.79 0.000
297 MRAP2 melanocortin 2 receptor accessory protein 2 Spleen - 3.77 0.002
298 ITM2A integral membrane protein 2A Spleen + 3.77 0.007
299 MND1 meiotic nuclear divisions 1 Spleen + 3.76 0.002
300 AMIGO2 adhesion molecule with Ig-like domain 2 Spleen - 3.76 0.019
301 BCHE butyrylcholinesterase Spleen - 3.76 0.003
302 SHE Src homology 2 domain containing E Spleen - 3.76 0.012
303 CD37 CD37 molecule Spleen - 3.76 0.042
304 JUN jun proto-oncogene Spleen - 3.76 0.013
305 GNG7 guanine nucleotide binding protein (G protein), gamma 7 Spleen - 3.75 0.000
306 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein Spleen - 3.74 0.006
307 EXO1 exonuclease 1 Spleen + 3.74 0.000
308 GNG12 guanine nucleotide binding protein (G protein), gamma 12 Spleen - 3.73 0.042
309 FAM129C family with sequence similarity 129, member C Spleen - 3.73 0.012
310 PTGDR prostaglandin D2 receptor (DP) Spleen + 3.72 0.000
311 AQP3 aquaporin 3 (Gill blood group) Spleen - 3.72 0.005
312 GINS1 GINS complex subunit 1 (Psf1 homolog) Spleen + 3.72 0.000
313 IGHA1 immunoglobulin heavy constant alpha 1 Spleen - 3.72 0.005
314 POLE2 polymerase (DNA directed), epsilon 2, accessory subunit Spleen + 3.72 0.000
315 CDH2 cadherin 2, type 1, N-cadherin (neuronal) Spleen - 3.71 0.016
316 NPR3 natriuretic peptide receptor 3 Spleen - 3.71 0.000
317 GALNT15 polypeptide N-acetylgalactosaminyltransferase 15 Spleen - 3.71 0.000
318 TRIP13 thyroid hormone receptor interactor 13 Spleen + 3.70 0.001
319 DUSP1 dual specificity phosphatase 1 Spleen - 3.70 0.002
320 GLI3 GLI family zinc finger 3 Spleen + 3.68 0.004
321 AQP9 aquaporin 9 Spleen - 3.68 0.049
322 PLEKHA5 pleckstrin homology domain containing, family A member 5 Spleen + 3.67 0.001
323 NRN1 neuritin 1 Spleen - 3.67 0.004
324 PNOC prepronociceptin Spleen - 3.67 0.008
325 CAMTA1 calmodulin binding transcription activator 1 Spleen - 3.67 0.008
326 SNCAIP synuclein, alpha interacting protein Spleen - 3.67 0.026
327 OLFM1 olfactomedin 1 Spleen - 3.66 0.000
328 AFF3 AF4/FMR2 family, member 3 Spleen - 3.66 0.008
329 TMEM100 transmembrane protein 100 Spleen - 3.66 0.038
330 SPC24 SPC24, NDC80 kinetochore complex component Spleen + 3.66 0.004
331 HELLS helicase, lymphoid-specific Spleen + 3.65 0.000
332 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) Spleen - 3.65 0.036
333 ITGA6 integrin, alpha 6 Spleen - 3.64 0.011
334 ZWINT ZW10 interacting kinetochore protein Spleen + 3.64 0.000
335 IL13RA1 interleukin 13 receptor, alpha 1 Spleen - 3.64 0.028
336 NDN necdin, melanoma antigen (MAGE) family member Spleen - 3.63 0.032
337 BTNL9 butyrophilin-like 9 Spleen - 3.63 0.020
338 KIF18A kinesin family member 18A Spleen + 3.63 0.000
339 AS3MT arsenite methyltransferase Spleen - 3.63 0.033
340 EGFL7 EGF-like-domain, multiple 7 Spleen - 3.62 0.002
341 EOMES eomesodermin Spleen + 3.62 0.001
342 FAM107A family with sequence similarity 107, member A Spleen - 3.62 0.020
343 TMEFF1 transmembrane protein with EGF-like and two follistatin-like domains 1 Spleen + 3.61 0.013
344 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) Spleen - 3.61 0.013
345 BHLHE41 basic helix-loop-helix family, member e41 Spleen - 3.61 0.031
346 CDCA3 cell division cycle associated 3 Spleen + 3.59 0.001
347 CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) Spleen - 3.59 0.009
348 PRDM16 PR domain containing 16 Spleen + 3.58 0.000
349 C18orf54 chromosome 18 open reading frame 54 Spleen + 3.57 0.002
350 ANGPTL2 angiopoietin-like 2 Spleen - 3.57 0.034
351 DOCK5 dedicator of cytokinesis 5 Spleen - 3.57 0.001
352 LRIG3 leucine-rich repeats and immunoglobulin-like domains 3 Spleen - 3.56 0.002
353 ARHGAP24 Rho GTPase activating protein 24 Spleen - 3.55 0.000
354 AURKA aurora kinase A Spleen + 3.55 0.001
355 AREG amphiregulin Spleen + 3.55 0.032
356 RAD51 RAD51 recombinase Spleen + 3.55 0.000
357 IL7R interleukin 7 receptor Spleen - 3.54 0.026
358 FAM9C family with sequence similarity 9, member C Spleen - 3.54 0.008
359 FAM150B family with sequence similarity 150, member B Spleen - 3.53 0.008
360 C5AR1 complement component 5a receptor 1 Spleen - 3.52 0.048
361 CD8B CD8b molecule Spleen + 3.52 0.039
362 NRXN3 neurexin 3 Spleen - 3.52 0.005
363 TCF19 transcription factor 19 Spleen + 3.52 0.000
364 CDRT4 CMT1A duplicated region transcript 4 Spleen + 3.52 0.019
365 CD3G CD3g molecule, gamma (CD3-TCR complex) Spleen + 3.52 0.002
366 PROK2 prokineticin 2 Spleen - 3.51 0.006
367 CSF3R colony stimulating factor 3 receptor (granulocyte) Spleen - 3.51 0.001
368 TLR10 toll-like receptor 10 Spleen - 3.51 0.017
369 GMPR guanosine monophosphate reductase Spleen + 3.50 0.013
370 MMP16 matrix metallopeptidase 16 (membrane-inserted) Spleen + 3.50 0.001
371 DIAPH3 diaphanous-related formin 3 Spleen + 3.50 0.000
372 ASF1B anti-silencing function 1B histone chaperone Spleen + 3.49 0.001
373 FANCI Fanconi anemia, complementation group I Spleen + 3.47 0.001
374 GGH gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) Spleen + 3.46 0.002
375 MCM2 minichromosome maintenance complex component 2 Spleen + 3.46 0.000
376 KIFC1 kinesin family member C1 Spleen + 3.45 0.000
377 SH3RF3 SH3 domain containing ring finger 3 Spleen + 3.45 0.004
378 RACGAP1 Rac GTPase activating protein 1 Spleen + 3.45 0.000
379 PPP1R9A protein phosphatase 1, regulatory subunit 9A Spleen + 3.43 0.003
380 CENPN centromere protein N Spleen + 3.43 0.001
381 DNA2 DNA replication helicase/nuclease 2 Spleen + 3.42 0.000
382 CENPW centromere protein W Spleen + 3.41 0.001
383 CENPU centromere protein U Spleen + 3.39 0.000
384 WDHD1 WD repeat and HMG-box DNA binding protein 1 Spleen + 3.39 0.001
385 AKAP12 A kinase (PRKA) anchor protein 12 Spleen + 3.37 0.003
386 DSCC1 DNA replication and sister chromatid cohesion 1 Spleen + 3.36 0.001
387 ESPL1 extra spindle pole bodies like 1, separase Spleen + 3.36 0.000
388 MCM7 minichromosome maintenance complex component 7 Spleen + 3.36 0.001
389 ENPP5 ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative) Spleen + 3.35 0.000
390 MYH10 myosin, heavy chain 10, non-muscle Spleen + 3.34 0.009
391 LARP6 La ribonucleoprotein domain family, member 6 Spleen + 3.34 0.025
392 CENPK centromere protein K Spleen + 3.31 0.000
393 POLQ polymerase (DNA directed), theta Spleen + 3.29 0.000
394 TRDV3 T cell receptor delta variable 3 Spleen + 3.29 0.029
395 SLC25A15 solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 Spleen + 3.28 0.002
396 PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) Spleen + 3.28 0.001
397 THEMIS thymocyte selection associated Spleen + 3.28 0.000
398 PLEKHG4 pleckstrin homology domain containing, family G (with RhoGef domain) member 4 Spleen + 3.27 0.001
399 CMC1 C-x(9)-C motif containing 1 Spleen + 3.26 0.000
400 DPY19L2P2 DPY19L2 pseudogene 2 Spleen + 3.25 0.002
Search GEO for disease gene expression data for Hepatosplenic T-Cell Lymphoma.

Pathways for Hepatosplenic T-Cell Lymphoma

GO Terms for Hepatosplenic T-Cell Lymphoma

Biological processes related to Hepatosplenic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(showing 1, show less)
# Name GO ID Score Top Affiliating Genes
1 T cell activation GO:0042110 8.8 PIK3CD DPP4 CD7

Molecular functions related to Hepatosplenic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(showing 1, show less)
# Name GO ID Score Top Affiliating Genes
1 alpha-tubulin binding GO:0043014 8.62 SETD2 INO80

Sources for Hepatosplenic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....